{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:26:01Z","timestamp":1781108761929,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.virol.2022.12.014","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T08:10:39Z","timestamp":1672215039000},"page":"84-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The antiviral activity of tripartite motif protein 38 in hepatitis B virus replication and gene expression and its association with treatment responses during PEG-IFN-\u03b1 antiviral therapy"],"prefix":"10.1016","volume":"579","author":[{"given":"Haiying","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingjia","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guili","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2022.12.014_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1749-6632.1980.tb20614.x","article-title":"Immune interferon: some properties and functions","volume":"350","author":"Baron","year":"1980","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.virol.2022.12.014_bib2","doi-asserted-by":"crossref","first-page":"18211","DOI":"10.1073\/pnas.0706987104","article-title":"Blood gene expression signatures predict exposure levels","volume":"104","author":"Bushel","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2022.12.014_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008593","article-title":"Hepatitis B virus Core protein nuclear interactome identififies SRSF10 as a host RNA-binding protein restricting HBV RNA production","volume":"16","author":"Chabrolles","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2022.12.014_bib4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.clinre.2016.12.006","article-title":"Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-\u03b1-2a antiviral therapy","volume":"41","author":"Deng","year":"2017","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.virol.2022.12.014_bib5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.virol.2022.12.014_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/hep.23011","article-title":"Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain","volume":"50","author":"Gao","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.virol.2022.12.014_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0033-1345717","article-title":"The molecular virology of hepatitis B virus","volume":"33","author":"Glebe","year":"2013","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.virol.2022.12.014_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/imm.12841","article-title":"Genome-wide host RNA signatures of infectious diseases: discovery and clinical translation","volume":"153","author":"Gliddon","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.virol.2022.12.014_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/cmi.2016.66","article-title":"Multifaceted roles of TRIM38 in innate immune and inflammatory responses","volume":"14","author":"Hu","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.virol.2022.12.014_bib10","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.1500859","article-title":"TRIM38 negatively regulates TLR3\/4-mediated innate immune and inflammatory responses by two sequential and distinct mechanisms","volume":"195","author":"Hu","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2022.12.014_bib11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.immuni.2016.08.014","article-title":"Sumoylation promotes the stability of the DNA sensor cGAS and the adaptor STING to regulate the kinetics of response to DNA virus","volume":"45","author":"Hu","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.virol.2022.12.014_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/emmm.201100160","article-title":"Regulation of innate immune signalling pathways by the tripartite motif (TRIM) family proteins","volume":"3","author":"Kawai","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.virol.2022.12.014_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coviro.2021.04.009","article-title":"Hepatitis B virus-host interactions and novel targets for viral cure","volume":"49","author":"Ligat","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.virol.2022.12.014_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coi.2010.11.003","article-title":"New developments in the induction and antiviral effectors of type I interferon","volume":"23","author":"Liu","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.virol.2022.12.014_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.790036","article-title":"Interferon gamma-inducible protein 16 of peripheral blood mononuclear cells may sense hepatitis B virus infection and regulate the antiviral immunity","volume":"11","author":"Lu","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.virol.2022.12.014_bib16","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/apt.17124","article-title":"TRIM26 inhibits hepatitis B virus replication by promoting HBx degradation and TRIM26 genetic polymorphism predicts PegIFN\u03b1 treatment response of HBeAg-positive chronic hepatitis B Patients","volume":"56","author":"Luo","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.virol.2022.12.014_bib17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/v12030346","article-title":"The E3 ubiquitin ligase TRIM21 promotes HBV DNA polymerase degradation","volume":"12","author":"Mu","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2022.12.014_bib18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fimmu.2016.00609","article-title":"Type-I interferon responses: from friend to foe in the battle against chronic viral infection","volume":"7","author":"Murira","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2022.12.014_bib19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specifific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.virol.2022.12.014_bib20","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jhep.2017.12.007","article-title":"Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism","volume":"68","author":"Niu","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2022.12.014_bib21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.virol.2013.06.028","article-title":"Hepatitis B virus (HBV) induces the expression of interleukin-8 that in turn reduces HBV sensitivity to interferon-alpha","volume":"444","author":"Pollicino","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.virol.2022.12.014_bib22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hep.27323","article-title":"Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections","volume":"61","author":"Rehermann","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.virol.2022.12.014_bib23","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.virol.2022.12.014_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","article-title":"Hepatitis B virus biology","volume":"64","author":"Seeger","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.virol.2022.12.014_bib25","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3389\/fimmu.2018.01872","article-title":"Identification of TRIM14 as a type I IFN-stimulated gene controlling hepatitis B virus replication by targeting HBx","volume":"9","author":"Tan","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2022.12.014_bib26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/cmi.2016.67","article-title":"Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replication","volume":"15","author":"Tan","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.virol.2022.12.014_bib27","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.virol.2022.12.014_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105406","article-title":"TRIM56 impairs HBV infection and replication by inhibiting HBV core promoter activity","volume":"207","author":"Tian","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2022.12.014_bib29","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2022.12.014_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tim.2017.07.006","article-title":"Mechanisms of hepatitis B virus persistence","volume":"26","author":"Tsai","year":"2018","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.virol.2022.12.014_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1128\/JVI.01804-12","article-title":"TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity","volume":"87","author":"Uchil","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.12.014_bib32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/v13020279","article-title":"TRIMming Type \u2160 interferon-mediated innate immune response in antiviral and antitumor defense","volume":"13","author":"Wang","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2022.12.014_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2018.10.048","article-title":"What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats","volume":"156","author":"Ward","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virol.2022.12.014_bib34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.tim.2020.07.002","article-title":"Virus-host cell interplay during hepatitis E virus infection","volume":"29","author":"Wi\u00dfing","year":"2021","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.virol.2022.12.014_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.21037\/atm.2017.03.69","article-title":"Alpha-interferon treatment in hepatitis B","volume":"5","author":"Woo","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.virol.2022.12.014_bib36","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.virol.2022.12.014_bib37","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/17425255.2019.1678584","article-title":"Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B","volume":"15","author":"Yeh","year":"2019","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.virol.2022.12.014_bib38","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3748\/wjg.v17.i9.1152","article-title":"Hepatoma cell line HepG2.2.15 demonstrates distinct biological features compared with parental HepG2","volume":"17","author":"Zhao","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.virol.2022.12.014_bib39","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.4049\/jimmunol.1103506","article-title":"Tripartite motif-containing protein 38 negatively regulates TLR3\/4- and RIG-I-mediated IFN-beta production and antiviral response by targeting NAP1","volume":"188","author":"Zhao","year":"2012","journal-title":"J. Immunol."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682222002264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682222002264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:58:21Z","timestamp":1758589101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682222002264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":39,"alternative-id":["S0042682222002264"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2022.12.014","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The antiviral activity of tripartite motif protein 38 in hepatitis B virus replication and gene expression and its association with treatment responses during PEG-IFN-\u03b1 antiviral therapy","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2022.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}